133
Participants
Start Date
May 31, 2007
Primary Completion Date
August 31, 2008
Study Completion Date
August 31, 2008
Degarelix
"Experimental~Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 360 mg SC (by injection under the skin) given after 1, 4, 7, \& 10 months."
Degarelix
"Experimental~Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 480 mg SC (by injection under the skin) given after 1, 4, 7, \& 10 months."
Investigational site, Carmel
State College Urologic Association, State College
Urology of Virginia Research, Norfolk
The Urology Center, Greensboro
Grand Strand Urology, Myrtle Beach
South Florida Medical Research, Aventura
Florida Foundation for Healthcare Research, Ocala
Urology Centers of Alabama, Homewood
Regional Urology, Shreveport
South Orange County Medical Research Center, Laguna Woods
Urology Research Center, Seattle
Investigational site, Surrey
Investigational site, Victoria
Investigational site, Kentville
The Female/Male Health Centres, Ontario
Nemocnice Jindrichuv Hradec a.s., Hradec
Slezska nemocnice, Opava
Vseobecna fakultni nemocnice v Praze, Prague
Dombóvári Szent Lukács Egészségügyi Kht, Dombóvár
Borsod-Abaúj-Zemplé n Megyei Kórház és Egyetemi Oktató Kórház, Miskolc
Miskolc Megyei Jogú Város Önkormányzat Miskolci Egészségügyi Központ, Miskolc
Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ, Szeged
Private Medical Center, Arad
"Prof Dr Th Burghele Clinical Hospital", Bucharest
Dinu Uromedica, Bucharest
Fundeni Clinical Institute, Bucharest
E-Uro Medical Center S.R.L., Cluj-Napoca
Provita Center, Constanța
Sibiu County Clinical Hospital, Sibiu
Lead Sponsor
Ferring Pharmaceuticals
INDUSTRY